Pediatric IBD Drug Pipeline — PatSnap Eureka
Pediatric IBD Pipeline: IL-12/23, Vedolizumab & JAK Inhibitor Approaches
The pediatric IBD therapeutic landscape is evolving rapidly beyond anti-TNF agents. Gut-selective biologics, IL-12/23 pathway inhibitors, and JAK inhibitors are under active investigation—yet only two biologics carry formal pediatric approval. Explore the patent signals and clinical evidence shaping this pipeline.
Three Emerging Modalities Beyond Anti-TNF in Pediatric IBD
Pediatric-onset IBD presents with greater disease extent, higher genetic load, and more aggressive inflammation than adult IBD. PatSnap's life sciences intelligence platform reveals three modalities reshaping the treatment landscape for children who fail conventional therapy.
Vedolizumab (α4β7 Integrin Blockade)
A fully humanized IgG1 monoclonal antibody targeting the α4β7 integrin heterodimer, blocking interaction with MAdCAM-1 and preventing pathogenic T-cell trafficking into intestinal mucosa. The gut-selective mechanism—distinguishing it from natalizumab—is a critical advantage in children where systemic immunosuppression carries heightened risk. Millennium Pharmaceuticals (Takeda) holds active patents covering 300 mg IV induction dosing specifically for pediatric patients.
Off-label use; active pediatric IP (US, CA, AU)Ustekinumab (p40 Subunit Blockade)
A human IgG1κ monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23, blocking both Th1 and Th17 inflammatory axes. Approved for adult CD and UC, ustekinumab is used off-label in pediatric IBD. A Kyushu University case series evaluated it as first-line biologic in four biologic-naïve pediatric-onset CD patients, measuring serum IL-12/IL-23p40 as a pharmacodynamic biomarker. Next-generation selective anti-p19 (IL-23 only) agents are entering development pipelines.
Off-label pediatric; adult Phase III data availableJAK Inhibitors (Tofacitinib & Selective Agents)
Orally bioavailable small molecules suppressing cytokine signaling by blocking JAK-mediated phosphorylation. Tofacitinib (pan-JAK, preference for JAK1/JAK3) is FDA-approved for adult moderate-to-severe UC. Second-generation selective agents—filgotinib and upadacitinib (JAK1-selective)—are in development for IBD. In pediatric IBD, JAK inhibitor use is limited to combination/dual therapy case reports. Elevated infection risk and cardiovascular/thrombotic concerns require careful consideration in children.
Investigational / off-label in pediatric populationsAnti-IL-1β & IL-10 Pathway Approaches
Very-early-onset IBD (disease onset before age 6) frequently involves monogenic defects in IL-10 signaling or autoinflammatory phenotypes distinct from classical IBD. Anti-IL-1β therapy (canakinumab) is highlighted for VEO-IBD with autoinflammatory phenotype, with a CHOP retrospective study reporting clinical response after ≥6 months of therapy. Genetic variants in IL-10, IL10RA, IL10RB, and STAT3 are associated with pediatric IBD subtypes.
Emerging; high unmet need in VEO-IBD subgroupWhat the Data Show: Vedolizumab Leads Pediatric Evidence Base
The strongest clinical signals in this dataset relate to vedolizumab. A systematic review of 10 studies encompassing 455 pediatric patients reported pooled 1-year clinical remission rates of 46% for Crohn's disease and 45% for UC/IBD-U—consistent with the adult GEMINI trial findings. An Austrian retrospective cohort (n=12, ages 8–17) evaluating vedolizumab after TNF-α antagonist failure identified both clinical responders and primary non-responders, including a severe systemic allergic reaction event.
A Stanford-based retrospective cohort described tacrolimus bridging during vedolizumab induction (n=12, median age 16) as a colectomy-prevention strategy in pediatric severe corticosteroid- and anti-TNF-refractory colitis—addressing the slow-onset pharmacodynamic profile of vedolizumab during the critical induction window.
For IL-12/23 inhibition, pediatric evidence is limited to a small case series (n=4) from Kyushu University evaluating ustekinumab as first-line biologic in pediatric-onset CD. Adult Phase III data from the UNIFI and CERTIFI trials are extensively referenced but not directly replicated in pediatric controlled trials within this dataset.
For JAK inhibitors, no pediatric-specific controlled trial data appear in the retrieved dataset. References to tofacitinib in pediatric IBD are limited to combination/dual therapy case reports. The PatSnap life sciences platform enables tracking of emerging pediatric trial registrations as they are filed.
- 10 studies, 455 patients in vedolizumab systematic review
- Tacrolimus bridging strategy documented at Stanford for acute severe colitis
- VEO-IBD vedolizumab safety data from Children's Memorial Health Institute, Warsaw
- No pediatric controlled trial data for JAK inhibitors in this dataset
- Canakinumab clinical response data for VEO-IBD autoinflammatory phenotype (CHOP)
Key Data Points from the Pediatric IBD Pipeline Dataset
Patent filings, remission data, and molecular target coverage synthesized from retrieved patent and literature records via PatSnap analytics.
Vedolizumab 1-Year Remission: CD vs UC/IBD-U in Pediatric Patients
Pooled data from a systematic review of 10 studies (455 pediatric patients). Remission rates are broadly comparable across disease types.
Molecular Targets Addressed in Pediatric IBD Pipeline
Key molecular targets identified across retrieved patent and literature records, mapped to therapeutic modality and disease subgroup.
Pediatric IBD Patent Landscape: Assignee Activity & Jurisdiction Coverage
Patent activity is concentrated in a single assignee cluster. Millennium Pharmaceuticals (Takeda) accounts for all identified pediatric IBD-specific patent filings in this dataset. Explore the full IP landscape using PatSnap IP analytics.
| Patent / Application | Assignee | Year | Jurisdiction | Status | Modality |
|---|---|---|---|---|---|
| Method of treating pediatric disorders | Millennium Pharmaceuticals, Inc. (Takeda) | 2018 | WO (PCT) | Filed | Vedolizumab / α4β7 |
| Method of treating pediatric disorders | Millennium Pharmaceuticals, Inc. (Takeda) | 2020 | US | Pending | Vedolizumab / α4β7 |
| Method of treating pediatric disorders | Millennium Pharmaceuticals, Inc. (Takeda) | 2018 | CA | Pending | Vedolizumab / α4β7 |
| Method of treating pediatric disorders with antibodies specific for α4β7 integrin | Millennium Pharmaceuticals, Inc. (Takeda) | 2025 | AU | Active | Vedolizumab / α4β7 |
| Pediatric-specific IL-12/23 inhibitor patent | No assignee identified in dataset | — | — | Gap | IL-12/23 / Ustekinumab |
No competing assignees for IL-12/23 or JAK inhibitor pediatric patents in this dataset
This represents a significant IP white space opportunity. Use PatSnap Eureka to monitor new filings in real time.
Combination Approaches & Next-Generation Strategies
Retrieved results signal multiple combination and next-generation strategies for refractory pediatric IBD, with dual biologic therapy and precision medicine frameworks as near-term clinical priorities.
Dual Biologic & Biologic + JAK Combinations
A Warsaw-based literature review documents dual biologic therapy in pediatric IBD, including anti-TNF + vedolizumab, anti-TNF + ustekinumab, and vedolizumab + tofacitinib combinations. An adult-focused review identifies vedolizumab + ustekinumab and vedolizumab + anti-TNF as most-used combinations for refractory CD, and vedolizumab + tofacitinib for refractory UC.
Selective Anti-p19 (IL-23 Specific) Agents
University of Leuven results signal that next-generation selective anti-IL-23 p19 agents (distinct from p40-targeting ustekinumab) are in development for IBD, noting their efficacy and distinguishing their expected profile from IL-17 inhibitors that have failed in Crohn's disease clinical trials.
Tacrolimus Bridging During Vedolizumab Induction
The Stanford pediatric colitis cohort signals a strategy of calcineurin inhibitor bridge therapy during the slow-onset vedolizumab induction period as a practical approach in acute severe pediatric colitis, addressing the pharmacodynamic lag before vedolizumab achieves full clinical effect.
T Cell Trafficking Inhibition Beyond α4β7
The Children's Health Ireland review signals emerging interest in additional anti-trafficking strategies targeting T cell subsets in pediatric IBD beyond the vedolizumab mechanism, pointing toward next-generation anti-integrin or lymphocyte-homing approaches as a future development direction.
Who Is Driving Pediatric IBD Innovation?
Patent activity in this dataset is concentrated in a single assignee cluster. Millennium Pharmaceuticals, Inc. (a Takeda subsidiary) accounts for all four identified patents—filed in WO, US, CA, and AU jurisdictions—all directed to pediatric IBD treatment methods using vedolizumab. The US and CA applications carry pending legal status, and the most recent AU continuation application (2025) remains active, indicating sustained IP investment in the pediatric vedolizumab indication.
No competing assignees filed pediatric-specific IL-12/23 or JAK inhibitor patents within this dataset—representing a significant IP white space for competitors and new entrants. Organisations tracking this space can use PatSnap patent analytics to monitor new filings as they emerge.
Literature activity is distributed across multiple academic medical centers and children's hospitals in South Korea, Poland, Japan, Italy, the United States, and Australia. Key contributing institutions include Children's Memorial Health Institute (Warsaw), Samsung Medical Center / Sungkyunkwan University (Seoul), Kyushu University (Japan), Children's Hospital of Philadelphia (USA), IRCCS Humanitas Research Hospital (Milan), and WHO-recognised children's health centres in Ireland and Australia.
The dataset is predominantly literature-driven for JAK inhibitor and IL-12/23 modalities, while vedolizumab in pediatric IBD shows both patent (commercial IP) and literature (real-world clinical) activity—the most mature evidence profile of the three modalities. Explore the full PatSnap customer case studies to see how pharma teams track competitive pipelines.
What This Pipeline Means for Drug Developers & IP Teams
Five strategic signals derived from patent and literature analysis via PatSnap Eureka, relevant to biopharma R&D, IP strategy, and clinical development teams.
Vedolizumab Pediatric IP Is Dominated by a Single Assignee
Millennium Pharmaceuticals (Takeda) holds pending patent claims in the US, CA, and AU covering vedolizumab methods specifically for pediatric IBD, with the most recent AU filing active in 2025. Competitors developing anti-integrin biologics in the pediatric IBD space will need to navigate this IP landscape or develop differentiated dosing and formulation claims.
Monitor via PatSnap EurekaOff-Label Use Precedes Formal Approval Across All Three Modalities
In this dataset, vedolizumab, ustekinumab, and JAK inhibitors are all used off-label in children. Real-world pediatric evidence is accumulating through retrospective cohorts rather than controlled trials, creating a regulatory evidence gap that represents both a risk (limited label guidance) and an opportunity (first-mover advantage for formal pediatric indication holders).
First-mover regulatory opportunityVEO-IBD Requires Mechanistically Distinct Approaches
Retrieved results highlight that patients with disease onset before age 6—particularly those with IL-10/IL-10R pathway defects or autoinflammatory features—may require targeted interventions (anti-IL-1β, IL-10 pathway restoration) rather than conventional biologic escalation. This subgroup is underserved by current approved pediatric IBD therapies.
High unmet need subgroupCombination Therapy Safety & PK Data Are Critical Evidence Gaps
Dual biologic and biologic + JAK inhibitor combinations are emerging in refractory pediatric IBD. The combination therapy data in this dataset, while largely observational and drawn primarily from adult literature extrapolated to children, signals a clinical practice evolution toward combinations. Formal safety and PK data for these combinations in pediatric populations represent a critical regulatory and clinical evidence gap.
Pediatric PK data neededPediatric IBD Drug Pipeline — key questions answered
Infliximab and adalimumab are the only biologics with formal regulatory approval in pediatric IBD within the retrieved dataset. Retrieved results frame these as the benchmark class, with approximately 20–30% of patients failing to achieve primary response and further loss of response over time—generating the unmet need that IL-12/23, vedolizumab, and JAK inhibitor approaches seek to address.
Vedolizumab is a fully humanized IgG1 monoclonal antibody targeting the α4β7 integrin heterodimer, blocking its interaction with MAdCAM-1 and thereby preventing pathogenic T-cell trafficking into intestinal mucosa. The mechanism is gut-selective, distinguishing it from natalizumab (anti-α4), which carries systemic immunosuppression risks. This gut-selective profile is a critical consideration in children.
A systematic review of 10 studies (455 patients) reported pooled 1-year clinical remission rates of 46% for CD and 45% for UC/IBD-U.
Tofacitinib is FDA-approved for adults with moderate-to-severe UC; pediatric use referenced in this dataset is off-label or investigational. No pediatric-specific controlled trial data for JAK inhibitors appear in the retrieved dataset. References to tofacitinib in pediatric IBD are limited to combination/dual therapy case reports and review-level discussion.
VEO-IBD refers to very-early-onset IBD, where disease onset occurs before age 6. Retrieved results highlight that patients with disease onset before age 6—particularly those with IL-10/IL-10R pathway defects or autoinflammatory features—may require targeted interventions (anti-IL-1β, IL-10 pathway restoration) rather than conventional biologic escalation. This subgroup is underserved by current approved pediatric IBD therapies.
Millennium Pharmaceuticals, Inc. (a Takeda subsidiary) accounts for all 4 identified patents—filed in WO, US, CA, and AU jurisdictions—all directed to pediatric IBD treatment methods using vedolizumab. The US and CA applications carry pending legal status, and the most recent AU continuation application (2025) remains active, indicating sustained IP investment in the pediatric vedolizumab indication. No competing assignees filed pediatric-specific IL-12/23 or JAK inhibitor patents within this dataset.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About Pediatric IBDAccelerate Your Pediatric IBD Pipeline Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search patents, literature, and clinical signals across IL-12/23, vedolizumab, and JAK inhibitor modalities in one AI-powered platform.
References
- Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases — Children's Memorial Health Institute, Warsaw, 2021
- Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent — Samsung Medical Center / Sungkyunkwan University, 2022
- Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature — Children's Memorial Health Institute, Warsaw, 2022
- Method of treating pediatric disorders — Millennium Pharmaceuticals, Inc., 2018, WO [Patent]
- Method of treating pediatric disorders — Millennium Pharmaceuticals, Inc., 2020, US [Patent]
- Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin — Millennium Pharmaceuticals, Inc., 2025, AU [Patent]
- Efficacy and safety of vedolizumab for pediatrics with IBD: a systematic review — First Hospital of Jilin University, 2022
- Ustekinumab therapy and serum IL-12/IL-23p40 levels for biologic naïve pediatric-onset Crohn disease — Kyushu University, 2019
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease — Academic Medical Center, Amsterdam, 2017
- Canakinumab for the treatment of autoinflammatory VEO-IBD — Children's Hospital of Philadelphia, 2022
- The Era of Janus Kinase Inhibitors for IBD Treatment — Yonsei University Wonju College of Medicine, 2021
- Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab — IRCCS Humanitas Research Hospital, Milan, 2022
- New treatment options for IBD — University of Leuven, 2018
- Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis — Stanford, 2021
- Vedolizumab use after failure of TNF-α antagonists in children and adolescents with IBD — Paris Lodron University / Salzburg, 2018
- Opportunities to Target T Cell Trafficking in Pediatric IBD — Children's Health Ireland, Dublin
- Precision medicine for pediatric IBD: a perspective — Sungkyunkwan University, 2020
- Selecting the Best Combined Biological Therapy for Refractory IBD Patients — Instituto de Salud Carlos III, Madrid, 2022
- PubMed / NCBI — National Center for Biotechnology Information
- World Health Organization (WHO) — Global IBD Epidemiology Data
- National Institutes of Health (NIH) — IL-10 Pathway and VEO-IBD Research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.